← Eichor
Condition: Acute Myeloid Leukemia Refractory Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Acute Myeloid Leukemia Refractory

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
Phase 1 · 1 location(s) · Nanjing Chia-tai Tianqing Pharmaceutical · NCT06049667Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute M
Phase 1 · 22 location(s) · National Cancer Institute (NCI) · NCT06484062First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod
Phase 1 · 6 location(s) · Genmab · NCT07384715Olutasidenib in Relapsed IDH1 Mutated AML Patients Who Have Previously Received Venetoclax
Phase 2 · 1 location(s) · Timothy Pardee · NCT07471841Haplo-Cord HSCT for AML/MDS
NA · 4 location(s) · Fujian Medical University Union Hospital · NCT07588360A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/Phase 2 · 104 location(s) · Sumitomo Pharma America, Inc. · NCT04988555Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML
Phase 1/Phase 2 · 12 location(s) · Ascentage Pharma Group Inc. · NCT04501120CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Phase 1 · 11 location(s) · Cullinan Therapeutics Inc. · NCT05143996Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/R
EARLY_Phase 1 · 1 location(s) · Hrain Biotechnology Co., Ltd. · NCT06760260Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Do
Phase 1 · 5 location(s) · Celyad Oncology SA · NCT04167696A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Phase 1 · 14 location(s) · Ascentage Pharma Group Inc. · NCT04275518Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Underg
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03630991Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
Phase 1 · 11 location(s) · AvenCell Europe GmbH · NCT05949125BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1 · 1 location(s) · Eric Stephen Winer, MD · NCT05703542IS-free Treg HaploHCT
Phase 1 · 1 location(s) · Dana-Farber Cancer Institute · NCT04678401Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Terrence J Bradley, MD · NCT05597306Safety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07297576Individualized AML Treatment
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07613385Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 7 location(s) · Nerviano Medical Sciences · NCT06549790Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Phase 2 · 12 location(s) · Children's Hospital of Soochow University · NCT06316960Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia
Phase 2 · 3 location(s) · Shanghai Jiao Tong University School of Medicine · NCT05870995Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT06084819Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
NA · 1 location(s) · European Institute of Oncology · NCT06785077Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
Phase 1 · 2 location(s) · iCell Gene Therapeutics · NCT07668557Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 · 3 location(s) · M.D. Anderson Cancer Center · NCT03383575uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Phase 1 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07109518Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Pacylex Pharmaceuticals · NCT06613217A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
Phase 1 · 4 location(s) · NovaOnco Therapeutics Co., Ltd. · NCT06820268
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.